AMENDMENT

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

In the Claims:

Please enter rewritten Claims 1-2, 11-14, 17 and new Claims 37-51 as follows. Please cancel Claims 3-4 and 22-36 without prejudice or disclaimer.

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A compound according to formula (I),



(I)

or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein:

X is $-NR_6S(O)_pR_{16}$;

W is hydrogen or $-(CR_7R_8)_q-W_1$;

W_1 is hydrogen or may be taken together with R_6 to define a bond so that X and W are joined together to form a five to seven membered heterocyclic ring;

Z is **~~a 5-membered heteroaryl group optionally substituted with 1-3 R_9, a five to six membered heterocyclo or cycloalkyl group optionally substituted with~~**

~~1-3 R_9, a 9 to 10 membered bicyclic aryl or heteroaryl~~ **isoquinolyl** optionally substituted with 1-3 substituents selected from R_9 and/or R_{10}, ~~or~~  ;

~~Z_1, Z_2 and Z_3 are independently N or CR_9;~~

R_1, R_2 and R_3 are attached to any available carbon atom of the phenyl ring and are independently selected from hydrogen, halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{1-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_6 is hydrogen, C_{1-4}alkyl, NH_2, C_{1-4}alkylamino, hydroxy, or C_{1-4}alkoxy, or together with W_1 is a bond so that X and W join together to form a five to seven membered heterocyclic ring;

R_7 and R_8 are independently selected from hydrogen, $-OR_{18}$, $-NR_{18}R_{19}$, $-NR_{18}SO_2R_{20}$, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl in turn optionally substituted with 1-3 of halogen, cyano, haloalkyl, haloalkoxy, nitro, hydroxy, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, amino, $NH(C_{1-4}alkyl)$, $N(C_{1-4}alkyl)_2$, and C_{1-4}aminoalkyl;

R_9, **and** R_{10} ~~and R_{11}~~ are independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl~~, provided that R_{11} is not $-C(=NR_{22})NR_{23}R_{24}$ when W or W_1 is hydrogen~~; wherein when R_9, **or** R_{10} ~~or R_{11}~~ is selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted

with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4} alkylamino, and/or cyano;

R_{12}, R_{13}, R_{14}, R_{18}, R_{19}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{15}, R_{20} and R_{21} are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{16} is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclo;

p is 1 or 2;

q is 1, 2 or 3;

t is 1 or 2; and

u is 1 or 2;

provided that:

~~**i) when Z is phenyl, pyridyl or pyridazinyl, R_9, R_{10} and/or R_{11} are other than cyano or $-C(=NR_{22})NR_{23}R_{24}$;**~~

~~**ii) when W is H or C_{1-4}alkyl, Z is other than aryl;**~~

~~**iii) when W is H, Z is other than C_{5-6}cycloalkyl, piperidinyl, tetrahydropyridinyl, 3-pyridyl, or 3-pyridyl *N*-oxide; or**~~

~~iv)~~ R_1, R_2, and R_3 are not all simultaneously hydrogen.

2. (Currently amended) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein:

X is $-NR_6S(O)_pR_{16}$;

W is hydrogen or $-(CH_2)_q$-H;

Z is ~~**selected from a 5-membered heteroaryl group optionally substituted with 1-3 R_9, a five to six membered heterocyclo or cycloalkyl group optionally substituted**~~

~~with 1-3 R_9, a 9 to 10 membered bicyclic aryl or heteroaryl~~ **isoquinolyl** optionally substituted with 1-3 substituents selected from R_9 and/or R_{10}~~, and~~



;

~~Z_1, Z_2 and Z_3 are independently N or CR_9 and at least one of Z_1, Z_2 and Z_3 is N;~~

R_1, R_2 and R_3 are attached to any available carbon atom of the phenyl ring and are independently selected from hydrogen, halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{1-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_6 is hydrogen;

R_9, **and** R_{10} ~~and R_{11}~~ are independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl~~, provided that R_{11} is not $-C(=NR_{22})NR_{23}R_{24}$~~; wherein when R_9, **or** R_{10} ~~or R_{11}~~ is selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4} alkylamino, and/or cyano;

R_{12}, R_{13}, R_{14}, R_{18}, R_{19}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{15}, R_{20} and R_{21} are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{16} is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclo;

p is 1 or 2;

q is 1, 2 or 3;

t is 1 or 2; and

u is 1 or 2;

provided that:

~~**i) when Z is pyridyl or pyridazinyl, R_9, R_{10} and/or R_{11} are other than cyano or $-C(=NR_{22})NR_{23}R_{24}$;**~~

~~**ii) when W is H, Z is other than piperidinyl, tetrahydropyridinyl, 3-pyridyl, or 3-pyridyl *N*-oxide; or**~~

~~**iii)**~~ R_1, R_2, and R_3 are not all simultaneously hydrogen.

3-4. (Canceled)

5. (Original) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein the compound is of formula (Ia):



(Ia),

wherein:

Y is NH_2 or H;

R_1, R_2 and R_3 are attached to any available carbon atom of the phenyl ring and are independently selected from H, halogen, CN, NO_2, $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkenyl, substituted $C_{1\text{-}6}$alkyl, substituted $C_{2\text{-}6}$alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$,

$-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_9 is, independently at each occurrence, H, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, or C_{3-7}cycloalkyl~~, provided that R_{11} is not $-C(=NR_{22})NR_{23}R_{24}$~~; wherein when R_9 is selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4} alkylamino, and/or cyano;

R_{16} is C_{1-6}alkyl substituted with 0-3 R_{25}, phenyl substituted 0-3 R_{25}, naphthyl substituted with 0-3 R_{25}, a 5-10 membered heteroaryl substituted with 0-3 R_{25} and selected from 1H-pyrazol-4-yl, 1H-pyrazol-4-yl, thiazol-5-yl, 2-naphthyl, quinolin-8-yl, benzo[1,2,5]thiadiazol-4-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, or 1H-benzoimidazol-5-yl;

R_{25} is, independently at each occurrence, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, cyano, carboxy, nitro, phenyl, $-SO_2NR_{22}R_{23}$, or $-CO\ NR_{22}R_{23}$; and

r is 0 to 2.

6. (Original) A compound according to claim 5, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein the compound is of formula (Ib):



(Ib),

wherein:

Y is H or NH_2;

R_{16} is Me, Et, Pr, i-Pr, cyclo-Pr, Bu, i-Bu, t-Bu, phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-OH-phenyl, 3-OH-phenyl, 4-OH-phenyl, 2-OMe-phenyl, 3-OMe-phenyl, 4-OMe-phenyl, 2-CH_2OH-phenyl, 3-CH_2OH-phenyl, 4-CH_2OH-phenyl, 2-CO_2H-phenyl, 3-CO_2H-phenyl, 4-CO_2H-phenyl, 3-$CONH_2$-phenyl, 4-$CONH_2$-phenyl, 3-CO_2H-4-OH-phenyl, 3-SO_2NH_2-phenyl, 4-SO_2NH_2-phenyl, 2-CN-phenyl, 3-CN-phenyl, 4-CN-phenyl, 3-NO_2-phenyl, 4-NO_2-phenyl, 2-NH_2-phenyl, 3-NH_2-phenyl, 4-NH_2-phenyl, 3-CH_2NH_2-phenyl, 4-CH_2NH_2-phenyl, 4-(2-$CH_2CH_2NH_2$)-phenyl, 4-(2-*tert*-butyl cabamoyl-ethyl)-phenyl, benzyl, 5-Cl-1,3-diMe-1H-pyrazol-4-yl, 5-Me-1-phenyl-1H-pyrazol-4-yl, 2,4-diMe-thiazol-5-yl, 2-naphthyl, Quinolin-8-yl, Benzo[1,2,5]thiadiazol-4-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, 2-amino-1H-benzoimidazol-5-yl, hydroxymethyl, hydroxyethyl, hydroxypropyl, aminomethyl, aminoethyl, aminopropyl, 2,2,2-trifluoroethyl, 3-SO_2NH_2-propyl, 3-$CONH_2$-propyl, 2-SO_2NH_2-ethyl, 2-$CONH_2$-ethyl, 4-SO_2NH_2-butyl, or 4-$CONH_2$-butyl.

7. (Original) A compound according to claim 6, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein the compound is of formula (Ib) wherein R_1 and R_2 are C_{1-4}alkoxy.

8. (Original) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein R_1 and R_2 are OR_{12}.

9. (Original) A compound according to claim 8, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein R_{12} is hydrogen, C_{1-6}alkyl, phenyl, or benzyl optionally substituted with 1-2 halogen, cyano, haloalkyl, haloalkoxy, nitro, hydroxy, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, amino, $NH(C_{1-4}alkyl)$, and/or $N(C_{1-4}alkyl)_2$.

10. (Original) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein W is hydrogen.

11. (Currently amended) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein Z is selected from:





~~Z_4 is fused to ring A comprising the common carbon atom C* and is~~



~~Z_5 is fused to ring A comprising the common carbon atom C* and is selected from:~~



Z_6 is fused to ring A comprising the common carbon atom C* and is



Z_7 is fused to ring A comprising the common carbon atom C* and is selected from:



~~Z_8 is fused to ring B comprising the common nitrogen atom N* and is selected from~~



~~Z_9 is CH or N;~~

r is 0, 1, or 2; and

s is 0, 1, 2, or 3.

12. (Currently amended) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt or hydrate thereof, wherein Z is selected from:



and



13. (Currently amended) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein the compound is of formula (Ic):



(Ic)

wherein:

X is $-NR_6S(O)_pR_{16}$;

W is hydrogen or $-(CH_2)_q$-H;

Z is ~~a 5-membered heteroaryl group optionally substituted with 1-2 R_9, a five to six membered heterocyclo or cycloalkyl group optionally substituted with 1-2 R_9, a 9 to 10 membered bicyclic aryl or heteroaryl~~ **isoquinolyl** optionally substituted with



1-3 substituents selected from R_9 and/or R_{10}~~, or~~;

~~Z_1, Z_2 and Z_3 are independently N or CR_9 and at least one of Z_1, Z_2 and Z_3 is N;~~

R_1 and R_2 are independently hydrogen, halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{2-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, or heterocyclo;

R_6 is hydrogen or together with W is a bond so that X and W join together to form a five to seven membered heterocyclic ring;

R_9; **and** R_{10} ~~**and R_{11}**~~ are independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl~~, provided that R_{11} is not $-C(=NR_{22})NR_{23}R_{24}$~~; wherein when R_9; **or** R_{10} ~~**or R_{11}**~~ is selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

R_{12}, R_{13}, R_{14}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{15} and R_{21} are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{16} is C_{1-6}alkyl substituted with 0-2 R_{25}, phenyl substituted 0-3 R_{25}, naphthyl substituted with 0-3 R_{25}, a 5-10 membered heteroaryl substituted with 0-3 R_{25} and selected from 1H-pyrazol-4-yl, 1H-pyrazol-4-yl, thiazol-5-yl, 2-naphthyl, quinolin-8-yl, benzo[1,2,5]thiadiazol-4-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, or 1H-benzoimidazol-5-yl;

R_{25} at each occurrence is selected from C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

p is 1 or 2;

q is 1, 2 or 3;

t is 1 or 2; and

u is 1 or 2~~;~~

~~**provided that when Z is pyridyl or pyridazinyl, R_9, R_{10} and/or R_{11} are other than cyano or $-C(=NR_{22})NR_{23}R_{24}$**~~.

14. (Currently amended) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein the compound is of formula (Id):



(Id)

wherein:

X is $-NR_6S(O)_pR_{16}$;

W is hydrogen or $-(CH_2)_p-W_1$;

W_1 is hydrogen or may be taken together with R_6 to define a bond so that X and W are joined together to form a five to seven membered heterocyclic ring;

Z is selected from:



and

~~Z_1, Z_2 and Z_3 are independently N or CR_9;~~

~~Z_4 is fused to ring A comprising the common carbon atom C* and is~~



~~Z_5 is fused to ring A comprising the common carbon atom C* and is selected from:~~



Z_6 is fused to ring A comprising the common carbon atom C* and is



Z_7 is fused to ring A comprising the common carbon atom C* and is selected from:



~~Z_8 is fused to ring B comprising the common nitrogen atom N* and is selected from~~



~~Z_9 is CH or N;~~

R_6 is hydrogen or together with W_1 is a bond so that X and W join together to form a five to seven membered heterocyclic ring;

R_9~~, R_{10}, and R_{11} are~~ is independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, , $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl, provided that R_9~~, R_{10}, and R_{11} are~~ is not $-C(=NR_{22})NR_{23}R_{24}$ when W or W_1 is hydrogen; wherein when R_9~~, R_{10} or R_{11}~~ is independently selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

R_{12}, R_{12a}, R_{12b}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{16} is C_{1-6}alkyl substituted with 0-2 R_{25}, phenyl substituted 0-3 R_{25}, naphthyl substituted with 0-3 R_{25}, a 5-10 membered heteroaryl substituted with 0-3 R_{25} and selected from 1H-pyrazol-4-yl, 1H-pyrazol-4-yl, thiazol-5-yl, 2-naphthyl, quinolin-8-yl, benzo[1,2,5]thiadiazol-4-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, or 1H-benzoimidazol-5-yl;

R_{21} is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{25} at each occurrence is selected from C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

p is 1 or 2;

q is 1, 2 or 3;

r is 0, 1, or 2;

s is 0, 1, 2, or 3;

t is 1 or 2; and

u is 1 or 2~~;~~

~~**provided that:**~~

~~**i) when Z is phenyl, pyridyl or pyridazinyl, R_9, R_{10} and/or R_{11} are other than cyano or $-C(=NR_{22})NR_{23}R_{24}$; or**~~

~~**ii) when W is H or C_{1-3}alkyl, Z is other than aryl**~~.

15. (Original) A compound of Claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein the compound is of formula (Ie):



(Ie)

16. (Original) A compound of Claim 15, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein the compound is of formula (If):



(If)

17. (Currently amended) A compound according to claim 1, wherein the compound is selected from the group:

~~*N*-[2-(3-ethoxy-4-isopropoxy-phenyl)-2-(1,2,3,4-tetrahydro-isoquinolin-7-ylamino)-acetyl]-benzenesulfonamide;~~

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-4-hydroxy-benzenesulfonamide;

4-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetylsulfamoyl]-benzoic acid;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-4-nitro-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-C-phenyl-methanesulfonamide;

naphthalene-2-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-4-methoxy-benzenesulfonamide;

4-amino-*N*-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

3-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetylsulfamoyl]-benzoic acid;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-4-methyl-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-4-fluoro-benzenesulfonamide;

methanesulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

ethane-1-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

propane-2-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

2-methyl-propane-2-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-3-fluoro-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-3-nitro-benzenesulfonamide;

benzo[1,2,5]thiadiazole-4-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

quinoline-8-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

3-amino-*N*-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

2,4-dimethyl-thiazole-5-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

5-methyl-1-phenyl-1H-pyrazole-4-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-2-nitro-benzenesulfonamide;

(2-{4-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetylsulfamoyl]-phenyl}-ethyl)-carbamic acid *tert*-butyl ester;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-3-hydroxymethyl-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-4-hydroxymethyl-benzenesulfonamide;

5-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetylsulfamoyl]-2-hydroxy-benzoic acid;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-3-hydroxy-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-2-hydroxy-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-3-cyano-benzenesulfonamide;

N-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-3-methyl-benzenesulfonamide;

2-amino-*N*-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

4-(2-amino-ethyl)-*N*-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

4-aminomethyl-*N*-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

3-aminomethyl-*N*-[2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;

2-amino-1H-benzoimidazole-5-sulfonic acid [2-(1-amino-isoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-amide;

~~*N*-[2-(3-amino-benzo[d]isoxazol-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;~~

~~*N*-[2-(3-amino-1H-indazol-6-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;~~

~~*N*-[2-(2-amino-3H-benzoimidazol-5-ylamino)-2-(3-ethoxy-4-isopropoxy-phenyl)-acetyl]-benzenesulfonamide;~~

~~2-(4-aminoquinazolin-7-ylamino)-2-(3-ethoxy-4-isopropoxyphenyl)-*N*-(phenylsulfonyl)acetamide;~~

~~2-(4-aminoquinazolin-7-ylamino)-2-(3-ethoxy-4-isopropoxyphenyl)-*N*-(methylsulfonyl)acetamide;~~

2-(1-aminoisoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxyphenyl)-*N*-(2,2,2-trifluoroethylsulfonyl)acetamide;

2-(1-aminoisoquinolin-6-ylamino)-*N*-(cyclopropylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)acetamide;

2-(1-aminoisoquinolin-6-ylamino)-*N*-(3- aminosulfonyl -phenylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)acetamide;

2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)-*N*-(phenylsulfonyl)-acetamide;

N-(3-cyanophenylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)acetamide;

N-(3-aminosulfonyl -phenylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)acetamide;

N-(cyclopropylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)acetamide;

N-(3-carboxamide-phenylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)acetamide;

N-(2-aminoethylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)-2-(isoquinolin-6-ylamino)acetamide;

2-(1-aminoisoquinolin-6-ylamino)-*N*-(3-carboxamide-phenylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)acetamide;

2-(1-aminoisoquinolin-6-ylamino)-*N*-(3-carboxamide-phenylsulfonyl)-2-(3-ethoxy-4-isopropoxyphenyl)acetamide; **and**

2-(1-aminoisoquinolin-6-ylamino)-2-(3-ethoxy-4-isopropoxyphenyl)-N-(methylsulfonyl)acetamide~~, and~~

~~4-[3-benzenesulfonyl-5-(3-ethoxy-4-isopropoxy-phenyl)-4-oxo-imidazolidin-1-yl]-benzamidine~~; or a stereoisomer or pharmaceutically acceptable salt thereof.

18. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt, or hydrate thereof.

19. (Original) A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt, or hydrate thereof.

20. (Original) A method according to Claim 19, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

21. (Original) A method according to Claim 19, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling

catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

22-36. (Canceled)

37. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

38. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

39. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

40. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 7, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

41. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 8, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

42. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 9, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

43. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 10, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

44. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 11, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

45. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 12, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

46. (New) A method for treating thrombosis, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1, or a stereoisomer or a pharmaceutically acceptable salt thereof.

47. (New) A compound of formula (IV):



(IV)

wherein R_1, R_2, R_3, and R_9 are defined as in Claim 1; R_{20} is C_{1-4}alkyl or benzyl; PG is a protecting group independently selected at each occurence from the group: formyl, benzyl, p-methoxybenzyl, nitrobenzyl, 2,4-dimethoxybenzyl, triphenylmethyl, di-p-anisylmethyl, furylmethyl, C_{1-4}alkoxycarbonyl, C_{3-4} allyloxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, trimethylsilyl, t-Bu-diMe-silyl, C_{1-4}alkylidene, and benzylidene; r is 0, 1, or 2, and s is 1 or 2; when s is 2, both PG may be taken together with the nitrogen to which they are attached to form a phthalimide group.

48. (New) A process for preparing a compound of Claim 47, which comprises: contacting a compound of formula (II):



(II)

wherein LG is a leaving group selected from the group: halogen, mesylate, tosylate, benzenesulfonate, and trifluoromethanesulfonate;

with a compound of formula (III):



(III)

in the presence of a base selected from the group: diisopropylethylamine, triethylamine, potassium carbonate, potassium bicarbonate, and potassium phosphate.

49. (New) A process according to Claim 48, for preparing a compound of formula of (IVb):



(IVb)

which comprises: contacting a compound of formula (II), wherein R_{20} is benzyl;

with 

; in the presence of diisopropyl ethyl amine.

50. (New) A process for preparing a compound of Claim 47, which comprises: contacting a compound of formula (V):



(V)

with a compound of formula (VI):



(VI)

in the presence of a palladium catalyst selected from the group: palladium (II) chloride, palladium (II) acetate, tris(dibenzylideneacetone)dipalladium (0), tetrakis(triphenylphosphine)palladium (0), bis(tri-t-butylphosphine)palladium(0), and allylpalladium chloride dimer; or a copper catalyst selected from the group: copper (III) triflate, tetrakis(acetonitrile)copper(I), hexafluorophosphate, copper(I) iodide, and copper (II) acetate; a ligand selected from the group: 1,1'-bis(diphenylphosphino)ferrocene, (R or S)-1-(2-diphenylphosphino-1-napthyl)isoquinoline, triphenylphosphine, triphenylarsine, 1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride, tri-t-butylphosphine, tri-2-furylphosphine, (R or S)-2,2'-bis(diphenylphosphino)-1,1'-binapthyl (BINAP), (R or S)-2,2'-bis(di-p-tolylphosphino)-1,1'-binapthyl (Tol-BINAP), and N,N-diethylsalicylamide; and a base selected from potassium carbonate, potassium t-butoxide, tetrabutylammonium hydroxide, triethylamine, diisopropylethylamine, cesium carbonate, cesium acetate, and potassium phosphate.

51. (New) A process according to Claim 50, for preparing a compound of formula of (IVb):



(IVb)

which comprises: contacting a compound of formula (II), wherein R_{20} is methyl;

with 

;

in the presence of a palladium catalyst such as tris(dibenzylideneacetone)dipalladium (0); a ligand such as (R or S)-2,2'-bis(diphenylphosphino)-1,1'-binapthyl (BINAP); and a base selected from diisopropylethylamine, cesium carbonate, and potassium phosphate.